129 related articles for article (PubMed ID: 20337979)
1. Itraconazole for invasive fungal infection with pediatric malignancies.
Kobayashi R; Suzuki D; Yasuda K; Kobayashi K
Pediatr Int; 2010 Oct; 52(5):707-10. PubMed ID: 20337979
[TBL] [Abstract][Full Text] [Related]
2. [Correlations between drug plasma concentration and adverse effects in patients treated with itraconazole for pulmonary aspergilloma].
Maesaki S; Hashiguchi K; Tomiyama Y; Sasaki E; Miyazaki H; Miyazaki Y; Higashiyama Y; Tomono K; Tashiro T; Kohno S
Nihon Kokyuki Gakkai Zasshi; 1999 Nov; 37(11):875-9. PubMed ID: 18217308
[TBL] [Abstract][Full Text] [Related]
3. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of intravenous injecting itraconazole as empirical antifungal therapy for patients with hematological malignancies].
Luo CW; DU X; Guo R; Weng JY; Lu ZS; Wu SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1000-4. PubMed ID: 22931672
[TBL] [Abstract][Full Text] [Related]
5. [Significance of monitoring trough plasma concentration levels for invasive fungal infection prophylaxis with itraconazole oral solution in patients with hematological malignancies: a prospective study].
Kawano I; Matsumoto K; Jiromaru T; Jinnochi F; Semba Y; Sugio T; Sakamoto K; Saito N; Yoshida S; Henzan H; Takase K; Morita K; Eto T
Rinsho Ketsueki; 2016; 57(12):2475-2480. PubMed ID: 28090013
[TBL] [Abstract][Full Text] [Related]
6. Plasma Concentration of Itraconazole in Patients With Hematologic Malignancies Treated With Itraconazole Oral Solution.
Marumo A; Miyawaki S; Dan N; Ishiyama K
Ther Drug Monit; 2017 Jun; 39(3):229-234. PubMed ID: 28445212
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort.
Cheng S; Zhou JF; Zou P; Huang XJ; Jin J; Shen ZX
Chin Med J (Engl); 2011 Nov; 124(22):3670-5. PubMed ID: 22340222
[TBL] [Abstract][Full Text] [Related]
8. [Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole].
Toubai T; Tanaka J; Fujisawa F; Kondo Y; Imamura M; Ota S; Hashino S; Yonetumi M; Chiba K; Kondo T; Toyoshima N; Asaka M
Jpn J Antibiot; 2003 Feb; 56(1):61-5. PubMed ID: 12723400
[TBL] [Abstract][Full Text] [Related]
9. [Development of treatment adherence by jellification of itraconazole oral solution].
Wada H; Tanabe S; Ichikawa K; Sano F; Kubo Y; Matsuhashi Y; Nakanishi H; Tasaka T; Sugihara T
Jpn J Antibiot; 2009 Feb; 62(1):17-25. PubMed ID: 19378767
[TBL] [Abstract][Full Text] [Related]
10. [Itraconazole capsules as antifungal prophylaxis for neutropenic patients with hematological malignancies from a single institution].
Toubai T; Tanaka J; Ota S; Kato N; Umehara S; Kahata K; Toyoshima N; Asaka M; Imamura M
Jpn J Antibiot; 2005 Dec; 58(6):507-17. PubMed ID: 16521343
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of measuring the blood concentration of itraconazole oral solution in the field of hematology.
Shimoeda S; Nakagawa S; Kobayashi H; Yamato S; Kawano K; Ohta S
Biol Pharm Bull; 2010; 33(11):1861-6. PubMed ID: 21048312
[TBL] [Abstract][Full Text] [Related]
12. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea.
Kim JS; Cheong JW; Kim YK; Park J; Mun YC; Kang HJ; Yi HG; Lee JH; Kim YS; Ryoo HM; Kim SH; Kim HY; Kim JY; Lee DG; Kim HG; Kim H; Joo YD; Min YH
Ann Hematol; 2014 Jan; 93(1):33-42. PubMed ID: 23807252
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
Jeong SH; Kim DY; Jang JH; Mun YC; Choi CW; Kim SH; Kim JS; Park JS
Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
[TBL] [Abstract][Full Text] [Related]
14. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.
Nucci M; Biasoli I; Akiti T; Silveira F; Solza C; Barreiros G; Spector N; Derossi A; Pulcheri W
Clin Infect Dis; 2000 Feb; 30(2):300-5. PubMed ID: 10671332
[TBL] [Abstract][Full Text] [Related]
16. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.
Caillot D; Bassaris H; McGeer A; Arthur C; Prentice HG; Seifert W; De Beule K
Clin Infect Dis; 2001 Oct; 33(8):e83-90. PubMed ID: 11550120
[TBL] [Abstract][Full Text] [Related]
17. The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan.
Kobayashi R; Kaneda M; Sato T; Ichikawa M; Suzuki D; Ariga T
J Pediatr Hematol Oncol; 2008 Dec; 30(12):886-90. PubMed ID: 19131772
[TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy and safety of itraconazole injection/oral solution sequential therapy for treatment of invasive fungal infection in intensive care unit].
; Qui HB
Zhonghua Nei Ke Za Zhi; 2008 Dec; 47(12):1012-6. PubMed ID: 19134307
[TBL] [Abstract][Full Text] [Related]
19. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
[TBL] [Abstract][Full Text] [Related]
20. [Improvement of patient adherence by mixing oral itraconazole solution with a beverage (orange juice)].
Adachi Y; Sumikuma T; Kagami R; Nishio A; Akasaka K; Tsunemine H; Kodaka T; Hiramatsu Y; Tada H
Rinsho Ketsueki; 2010 May; 51(5):315-9. PubMed ID: 20534951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
